Senators Reintroduce Bill to Study FDI Effects on Pharmaceutical Industry
Two senators reintroduced a bill this month that would require the U.S. to conduct a study on the effects of foreign direct investment on the U.S. pharmaceuticals industry. The U.S. Pharmaceutical Supply Chain Review Act, reintroduced by Sens. Elizabeth Warren,…
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
D-Mass., and Marco Rubio, R-Fla., would require the Treasury Department to provide a report to Congress on how foreign direct investment “affects the nation's ability to produce drugs, as well as their key components.” It would also require a report about how foreign investment in “U.S. genome sequencing technologies affects domestic capacity to sequence or store DNA” and the number of transactions that the Committee on Foreign Investment in the U.S. has reviewed in the last year involving the “sequencing or storage of DNA.”